dc.contributor.author | Van der Kolk, WL | en_US |
dc.contributor.author | Van der Zee, AGJ | en_US |
dc.contributor.author | Slomovitz, BM | en_US |
dc.contributor.author | Baldwin, PJW | en_US |
dc.contributor.author | Van Doorn, HC | en_US |
dc.contributor.author | De Hullu, JA | en_US |
dc.contributor.author | Van der Velden, J | en_US |
dc.contributor.author | Gaarenstroom, KN | en_US |
dc.contributor.author | Slangen, BFM | en_US |
dc.contributor.author | Kjolhede, P | en_US |
dc.contributor.author | Brännström, M | en_US |
dc.contributor.author | Vergote, I | en_US |
dc.contributor.author | Holland, CM | en_US |
dc.contributor.author | Coleman, R | en_US |
dc.contributor.author | Van Dorst, EBL | en_US |
dc.contributor.author | Van Driel, WJ | en_US |
dc.contributor.author | Nunns, D | en_US |
dc.contributor.author | Widschwendter, M | en_US |
dc.contributor.author | Nugent, D | en_US |
dc.contributor.author | DiSilvestro, PA | en_US |
dc.contributor.author | Mannel, RS | en_US |
dc.contributor.author | Tjiong, MY | en_US |
dc.contributor.author | Boll, D | en_US |
dc.contributor.author | Cibula, D | en_US |
dc.contributor.author | Covens, A | en_US |
dc.contributor.author | Provencher, D | en_US |
dc.contributor.author | Runnebaum, IB | en_US |
dc.contributor.author | Monk, BJ | en_US |
dc.contributor.author | Zanagnolo, V | en_US |
dc.contributor.author | Tamussino, K | en_US |
dc.contributor.author | Oonk, MHM | en_US |
dc.contributor.author | all GROINSS-V I and II participants | en_US |
dc.date.accessioned | 2022-11-16T11:43:58Z | |
dc.date.available | 2022-07-18 | en_US |
dc.date.issued | 2022-10 | en_US |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/82483 | |
dc.description.abstract | OBJECTIVE: Optimal management of the contralateral groin in patients with early-stage vulvar squamous cell carcinoma (VSCC) and a metastatic unilateral inguinal sentinel lymph node (SN) is unclear. We analyzed patients who participated in GROINSS-V I or II to determine whether treatment of the contralateral groin can safely be omitted in patients with a unilateral metastatic SN. METHODS: We selected the patients with a unilateral metastatic SN from the GROINSS-V I and II databases. We determined the incidence of contralateral additional non-SN metastases in patients with unilateral SN-metastasis who underwent bilateral inguinofemoral lymphadenectomy (IFL). In those who underwent only ipsilateral groin treatment or no further treatment, we determined the incidence of contralateral groin recurrences during follow-up. RESULTS: Of 1912 patients with early-stage VSCC, 366 had a unilateral metastatic SN. Subsequently, 244 had an IFL or no treatment of the contralateral groin. In seven patients (7/244; 2.9% [95% CI: 1.4%-5.8%]) disease was diagnosed in the contralateral groin: five had contralateral non-SN metastasis at IFL and two developed an isolated contralateral groin recurrence after no further treatment. Five of them had a primary tumor ≥30 mm. Bilateral radiotherapy was administered in 122 patients, of whom one (1/122; 0.8% [95% CI: 0.1%-4.5%]) had a contralateral groin recurrence. CONCLUSION: The risk of contralateral lymph node metastases in patients with early-stage VSCC and a unilateral metastatic SN is low. It appears safe to limit groin treatment to unilateral IFL or inguinofemoral radiotherapy in these cases. | en_US |
dc.format.extent | 3 - 10 | en_US |
dc.language | eng | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Gynecol Oncol | en_US |
dc.rights | This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). | |
dc.subject | Inguinofemoral lymphadenectomy | en_US |
dc.subject | Lymph node metastases | en_US |
dc.subject | Radiotherapy | en_US |
dc.subject | Sentinel lymph node | en_US |
dc.subject | Vulvar cancer | en_US |
dc.subject | Carcinoma, Squamous Cell | en_US |
dc.subject | Female | en_US |
dc.subject | Groin | en_US |
dc.subject | Humans | en_US |
dc.subject | Lymph Node Excision | en_US |
dc.subject | Lymph Nodes | en_US |
dc.subject | Lymphadenopathy | en_US |
dc.subject | Lymphatic Metastasis | en_US |
dc.subject | Neoplasm Recurrence, Local | en_US |
dc.subject | Sentinel Lymph Node | en_US |
dc.subject | Sentinel Lymph Node Biopsy | en_US |
dc.subject | Vulvar Neoplasms | en_US |
dc.title | Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe. | en_US |
dc.type | Article | |
dc.rights.holder | © 2022 The Authors. Published by Elsevier Inc. | |
dc.identifier.doi | 10.1016/j.ygyno.2022.07.017 | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/36085090 | en_US |
pubs.issue | 1 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 167 | en_US |
dcterms.dateAccepted | 2022-07-18 | en_US |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |